There are no available data for remestemcel use in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with remestemcel to assess whether it can cause fetal harm when administered to a pregnant woman. It is not known if remestemcel has the potential to be transferred to the fetus. Therefore, remestemcel is not recommended for women who are pregnant. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 10-20%, respectively.
There is no information regarding the presence of remestemcel in human milk, the effect on the breastfed infant, and the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for remestemcel and any potential adverse effects on the breastfed infant from remestemcel or from the underlying maternal condition.
No animal studies have been performed to evaluate the effects of remestemcel on carcinogenesis, mutagenesis or impairment of fertility.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
The safety data described in this section reflect exposure to remestemcel in 54 patients in Study MSB-GVHD001 for the treatment of SR-aGvHD. Patients received intravenous infusion of remestemcel at a dosage of 2 x 106 MSCs/kg twice a week for four consecutive weeks, for a total of eight infusions. Patients with partial or mixed response at Day 28 received additional infusions of remestemcel 2 x 106 MSCs/kg once a week for an additional four weeks. The median number of doses administered were 10 (range 1 to 16), and the treatment was administered over a median of 43 days (range 1 to 104 days).
Serious adverse reactions occurred in 35 patients (65%) including pyrexia (n=5;9%), respiratory failure (n=5;9%), pneumatosis intestinalis (n=4;7%) and staphylococcal bacteremia (n=2;<5%). Eight patients had discontinuation of remestemcel treatment due to the following: acute infusion reactions (n=3), hypotension (n=1), gastroenteritis (n=1), and death (n=3).
Table 1 summarizes most common adverse reactions that occurred in ≥10% patients in Study MSB-GVHD001.
Table 1. Adverse Reactions** Occurring in ≥10% of Patients in Study MSB-GVHD001 (N=54):
| Adverse Reactions | All Gradesa n (%) | Grade 3 b n (%) |
|---|---|---|
| Viral infectious disorders* | 30 (56) | 8 (15) |
| Bacterial infectious disorders* | 24 (44) | 10 (19) |
| Infections - pathogen unspecified* | 22 (41) | 8 (15) |
| Pyrexia | 19 (35) | 2 (4) |
| Hemorrhage* | 15 (28) | 4 (7) |
| Edema* | 12 (22) | 1 (2) |
| Abdominal pain | 11 (20) | 4 (7) |
| Hypertension | 11 (20) | 3 (6) |
| Vomiting | 10 (19) | 3 (6) |
| Arrhythmia* | 9 (17) | 2 (4) |
| Diarrhea | 9 (17) | 1 (2) |
| Rash* | 9 (17) | 0 (0) |
| Arthralgia | 8 (15) | 0 (0) |
| Fungal infectious disorders* | 8 (15) | 2 (4) |
| Hypotension | 8 (15) | 2 (4) |
| Cough | 7 (13) | 0 (0) |
| Respiratory Failure | 6 (11) | 6 (11) |
a Based on National Cancer Institute Adverse Event Common Toxicity Criteria version 4.03
b No grade 4 or 5 adverse reactions occurred in the study
* Is a composite that includes multiple related terms
** Includes adverse reactions up to 100 days following remestemcel treatment
Table 2 presents the most common grade 3 or 4 laboratory abnormalities that worsened from baseline in ≥10% of patients
Table 2. Grade 3 or 4 Laboratory Abnormalities that Worsened from Baseline in ≥10% of Patients in Study MSB-GVHD001 (N=54):
| Laboratory Parameter | Grade 3 or highera % |
|---|---|
| Gamma-glutamyl transferase increased | 32 |
| Thrombocytopenia | 28 |
| Blood bilirubin increased | 11 |
a Based on National Cancer Institute Adverse Event Common Toxicity Criteria version 4.03
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.